3393-64-4Relevant articles and documents
Chelation, activation, and proximity effects in the deprotection of dithianes with ZnBr2. Applications in the polyketide field
Vakalopoulos,Hoffmann
, p. 2185 - 2188 (2001)
(Matrix presented) Double deprotection of dithiane aldol equivalents is feasible under mild conditions with ZnBr2 and suitably placed MEM, BOM, and SEM groups which function as protecting, activating, and regiodirecting groups. The procedure is useful in natural product synthesis.
Method for preparing 3, 4-dimethylpyrazole and phosphate thereof
-
Paragraph 0096; 0098; 0099; 0107; 0115; 0123, (2019/04/17)
The invention discloses a method for preparing 3, 4-dimethylpyrazole and phosphate thereof. The method for preparing the 3, 4-dimethylpyrazole includes the steps: (1) feeding 2-butanone, aldehyde andalkali solution into a microchannel reactor and performing aldehyde ketone condensation reaction to produce 4-hydroxy-3-methyl-2-butanone salt; (2) mixing reaction liquid obtained in the step (1) andacid liquid in the microchannel reactor to obtain 4-hydroxy-3-methyl-2-butanone water solution; (3) performing reaction on hydrazine hydrate and the 4-hydroxy-3-methyl-2-butanone water solution in themicrochannel reactor, mixing reaction liquid with the alkali solution and hydrogen peroxide, and performing oxidative dehydrogenation reaction to obtain 3, 4-dimethylpyrazole water solution; (4) performing organic extraction and distillation on the 3, 4-dimethylpyrazole water solution to obtain the 3, 4-dimethylpyrazole. According to the method, reaction time is greatly shortened, the yield and the purity of products are ensured, and continuous production can be realized.
COMPOUND AND METHOD FOR THE TREATMENT OF PAIN
-
Page/Page column 9, (2011/10/12)
The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications.